Year-round control for VKC
1
The first and only topical cyclosporine FDA-approved to treat
vernal keratoconjunctivitis (VKC) in children and adults
1
NOW AVAILABLE
Reduction in itching and keratitis scores
as early as month 1
1
Established 12-month safety profi le with low
rates of mild-to-moderate adverse events
1,3
Additional reductions in photophobia, mucous
discharge, and tearing observed over 4 months
in the pivotal multicenter trial
2
REFERENCES: 1. Verkazia [package insert]. Emeryville, CA: Santen Inc.; 2021. 2. Leonardi A, Doan S, Amrane M, et al; for VEKTIS Study Group.
A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology.
2019;126(5):671-681. doi:10.1016/j.ophtha.2018.12.027 3. Bremond-Gignac D, Doan S, Amrane M, et al; for VEKTIS Study Group. Twelve-
month results of cyclosporine A cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol.
2020;212:116-126. doi:10.1016/j.ajo.2019.11.020 4. US Department of Health and Human Services. Orange Book: Approved Drug Products
With Therapeutic Equivalence Evaluations. 42nd ed. US Government Publishing Offi ce; 2022. Accessed March 16, 2022. https://www.fda.gov/
media/71474/download
© 2022 Santen Inc. All rights reserved. VKC-US-220041
INDICATIONS AND USAGE
Verkazia
®
(cyclosporine ophthalmic
emulsion) 0.1% is a calcineurin inhibitor
immunosuppressant indicated for the
treatment of vernal keratoconjunctivitis
in children and adults.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Potential for eye injury and contamination:
To avoid the potential for eye injury and
contamination, advise patient not to touch
the vial tip to the eye or other surfaces.
ADVERSE REACTIONS
The most common adverse reactions
reported in greater than 5% of patients
were eye pain (12%) and eye pruritus
(8%), which were usually transitory and
occurred during instillation.
Harness the highest concentration of cyclosporine
available in an eye drop.
1,4
Visit verkazia.com to learn more
You are encouraged to report adverse reactions of prescription drugs to Santen at 1-855-7-SANTEN (1-855-772-6836). Or you
may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Brief Summary on adjacent page and Full Prescribing Information at verkazia.com.
